Compare HubSpot Inc (HUBS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Zimmer Biomet Holdings Inc — how do they compare? HubSpot Inc trades at $228.3 (market cap $11.56B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HUBS | ZBH | |
|---|---|---|
Market Cap | $11.56B | $16.95B |
Volume | 1,891,287 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $494.58 | $103.98 |
52-Week Low | $170.39 | $79.58 |
Typical Hold Time | 78 Days | 89 Days |
Enterprise Value | $10.46B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.84, up 5.23% over the past day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, improving profitability, and positive cash flow trends, supported by an AI-focused strategy unveiled at its recent Analyst Day. Analyst consensus is bullish with a $243.65 price target, though high valuation multiples and competitive pressures remain considerations.
The outlook for HUBS is positive, driven by AI integration, margin expansion targets, and consistent revenue growth. Key risks include elevated valuation metrics, potential AI-driven demand headwinds, and insider selling activity. The stock presents a growth opportunity but requires monitoring of execution against ambitious targets and competitive dynamics in the CRM software space.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
